JP2024088648A5 - - Google Patents

Info

Publication number
JP2024088648A5
JP2024088648A5 JP2024038682A JP2024038682A JP2024088648A5 JP 2024088648 A5 JP2024088648 A5 JP 2024088648A5 JP 2024038682 A JP2024038682 A JP 2024038682A JP 2024038682 A JP2024038682 A JP 2024038682A JP 2024088648 A5 JP2024088648 A5 JP 2024088648A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024038682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024088648A (ja
Filing date
Publication date
Priority claimed from GBGB1812382.8A external-priority patent/GB201812382D0/en
Application filed filed Critical
Publication of JP2024088648A publication Critical patent/JP2024088648A/ja
Publication of JP2024088648A5 publication Critical patent/JP2024088648A5/ja
Pending legal-status Critical Current

Links

JP2024038682A 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体 Pending JP2024088648A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1812382.8A GB201812382D0 (en) 2018-07-30 2018-07-30 Compounds
GB1812382.8 2018-07-30
JP2021529531A JP7805783B2 (ja) 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体
PCT/GB2019/052127 WO2020025942A1 (en) 2018-07-30 2019-07-30 Fluorinated bile acid derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021529531A Division JP7805783B2 (ja) 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体

Publications (2)

Publication Number Publication Date
JP2024088648A JP2024088648A (ja) 2024-07-02
JP2024088648A5 true JP2024088648A5 (enExample) 2026-01-22

Family

ID=63518053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021529531A Active JP7805783B2 (ja) 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体
JP2024038682A Pending JP2024088648A (ja) 2018-07-30 2024-03-13 フッ素化胆汁酸誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021529531A Active JP7805783B2 (ja) 2018-07-30 2019-07-30 フッ素化胆汁酸誘導体

Country Status (7)

Country Link
US (1) US11517577B2 (enExample)
EP (1) EP3830103B8 (enExample)
JP (2) JP7805783B2 (enExample)
CN (1) CN112771063B (enExample)
ES (1) ES2968881T3 (enExample)
GB (1) GB201812382D0 (enExample)
WO (1) WO2020025942A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820887D0 (en) * 2018-12-20 2019-02-06 Nzp Uk Ltd Compounds
CN118660883A (zh) * 2021-11-15 2024-09-17 海湃泰克(北京)生物医药科技有限公司 多环化合物及其方法
CN115819491A (zh) * 2022-12-22 2023-03-21 江苏佳尔科药业集团股份有限公司 7-酮基石胆酸及熊去氧胆酸的合成方法
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2253593C (en) 1996-05-23 2008-07-08 Novartis Ag Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
AU2009316484B2 (en) 2008-11-19 2015-04-16 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN112057457A (zh) 2013-03-13 2020-12-11 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
WO2015085474A1 (zh) 2013-12-10 2015-06-18 华为终端有限公司 一种注册方法和相关节点以及注册系统
BR112017009657A2 (pt) 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
KR102526632B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての6α−アルキル−6,7−ジオン−ステロイド
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN105348365A (zh) 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
JP2018507880A (ja) 2015-03-09 2018-03-22 インターセプト ファーマシューティカルズ, インコーポレイテッド 骨密度を調節する方法
CN107531741A (zh) 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸
US20160279393A1 (en) 2015-03-25 2016-09-29 Covidien Lp Guidewire retrieval catheter
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2016173493A1 (en) * 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
WO2016173397A1 (zh) 2015-04-28 2016-11-03 上海翰森生物医药科技有限公司 胆酸衍生物及其制备方法和医药用途
TW201704251A (zh) 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
CN106210599B (zh) 2015-04-30 2021-02-12 中兴通讯股份有限公司 一种多画面调整方法、装置及多点控制单元
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
BR112018001869A2 (pt) 2015-07-30 2018-09-18 Intercept Pharmaceuticals Inc método para preparação de ácidos biliares e derivados dos mesmos
EP3331896A4 (en) 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
AU2016326428A1 (en) 2015-09-21 2018-04-12 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
CN108348533A (zh) 2015-11-06 2018-07-31 英特塞普特医药品公司 制备奥贝胆酸及其衍生物的方法
CA3009149A1 (en) 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
CN105646634A (zh) 2016-01-29 2016-06-08 中国药科大学 奥贝胆酸杂质的制备方法
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EA038632B1 (ru) 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Similar Documents

Publication Publication Date Title
JP2024156852A5 (enExample)
JP2024133471A5 (enExample)
JP2026012786A5 (enExample)
JP2023113641A5 (enExample)
JP2025023938A5 (enExample)
JP2023113681A5 (enExample)
JP2024037765A5 (enExample)
JP2026048925A5 (enExample)
JP2025106258A5 (enExample)
JP2023134518A5 (enExample)
JP2023153863A5 (enExample)
JP2023164986A5 (enExample)
JP2025118771A5 (enExample)
JP2024156705A5 (enExample)
JP2025038009A5 (enExample)
JP2023134519A5 (enExample)
JP2022538004A5 (enExample)
JP2025163046A5 (enExample)
JP2023139025A5 (enExample)
JP2025143267A5 (enExample)
JP2025124655A5 (enExample)
JP2025041678A5 (enExample)
JP2023103231A5 (enExample)
JP2024160274A5 (enExample)
JP2023154065A5 (enExample)